NCT01594970View on ClinicalTrials.gov

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

PHASE4CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

Bimatoprost 0.01%

1 drop in the affected eye(s), administered in the evening for 12 weeks.

Trial Locations (1)

Unknown

Seoul

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01594970 - A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) | Biotech Hunter | Biotech Hunter